NCT04373564 2026-01-22
ODYSSEY
Guerbet
Phase 4 Recruiting
Clinical Trials
6 trialsNCT04524442 2025-01-24
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
Phase 4 Completed
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT01595009 2018-11-29
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
Novartis
Phase 4 Completed